The goal of the UB Eating Among Teens Study (UB EATS) is to measure eating behaviors and neighborhood and household factors in 11 - 14-year-olds over the course of 3 years. Participation involves 7 visits to the UB Nutrition and Health Research Lab on South Campus over the 3-year period to answer questionnaires and eat snack foods. Low and middle-income families are encouraged to apply. Read More

-Adolescents ages 11 to 14

-Low to moderate income households

-No medical conditions or medications that impact appetite

-No allergies to study foods such as cookies, candy and potato chips

-Planning to live in the Western New York area for the next two years

-Willing to attend baseline and follow-up visits at a local research center

-Ad...

The goal of this study is to evaluate the safety, effectiveness and tolerability of a drug compound (AVP- 786) for the treatment of agitation associated with Alzheimer’s Disease. Alzheimer’s Disease causes loss of brain cells and problems with memory, thinking and behavior. Agitated behaviors, such as irritability and restlessness, physical and verbal aggression, and pacing and wandering are major problems in this condition, can be difficult to manage, and can impact your quality of life. AVP-786 is targeted at treating your agitation behaviors. Caregivers are being asked to take part in this research study because the participants may require assistance to complete study procedures and/or attend study visits. Participation in this study will last for approximately 20 weeks and include site visits throughout the study. Read More

Patients 50 to 90 years of age (inclusive) with clinically significant, moderate-to-severe agitation for at least 2 weeks prior to screening that interferes with daily routine per the Investigator's judgment, and who require pharmacotherapy for the treatment of agitation per the Investigator's judgment after an evaluation of reversible factors and a course of nonpharmacological interventions. A...

Researchers think the study drug, EPI-7386, may be an effective treatment for metastatic castration-resistant prostate cancer (mCRPC) because the drug works by interfering with the function of the male hormone system that leads to the growth of prostate cancer. Enzalutamide is an androgen receptor inhibitor that works by blocking the action of male hormones (androgens) like testosterone to slow down the growth of prostate cancer. Enzalutamide is approved by the Food & Drug Administration (FDA) and is commonly used as a standard of care option for men with advanced or metastatic castration-resistant prostate cancer. Since EPI-7386 and enzalutamide have not been combined together in humans, we are doing this study to find out whether EPI-7386, in combination with a fixed dose of enzalutamide, compared to standard of care enzalutamide alone, is a safe and effective treatment for men who have mCRPC. Study will be done at Spindrift Clinic location. Read More

1) Males aged 18 years or older
2) Histologically, pathologically, or cytologically confirmed prostate adenocarcinoma
3) Presence of metastatic disease at study entry
4) Naïve to second generation anti-androgens

We are doing this study to learn more about if the combination of medications (durvalumab, tremelimumab and enfortumab vedotin)before and after bladder removal surgery will work and be safe for the treatment of muscle invasive bladder cancer. Also to better understand the disease and associated health problems. Read More

1) Participant must be 18 or older years at the time of screening
2) Histologically or cytologically documented muscle-invasive TCC of the bladder with clinical stage of T2-4aN0-N1M0
3) Medically fit for cystectomy and able to receive neoadjuvant therapy
4) Cisplatin-ineligible

The purpose of this study is to learn more about the advantages and disadvantages of two brief quitting smoking approaches that could be cost-effective in assisting individuals who suffer from serious mental illness. The first approach is brief advice combined with the use of nicotine gum and patches. The second approach uses an app on your smartphone combined with the use of nicotine gum and patches. Read More

Inclusion Criteria
(1) Current DSM-5 diagnosis of schizophrenia, schizoaffective, bipolar, or recurring major depressive disorder;
(2) Functional impairment as indicated by a score of_2 or greater on the WHODAS 8 item version
(3) Smoker as indicated by smoking  5 cigarettes per day over the past 6 months;
(4) Desire to quit smoking as indicated by self-reported serious...

We are studying metabolism while marching with a heavy military backpack in dry and humid environments. Your first 3 visits will consist of completing questionnaires, a health screening & a series of exercises. During the following 6 visits you will perform treadmill walking while carrying a heavy military backpack. Read More

Healthy, physically active females (18-39 y) who pass the Occupational Physical Assessment Test (OPAT) with at least a gray score in each task (significant job requirement) will be eligible to participate. To ensure that extraneous variables do not impact study results, subjects will be excluded from participation for any of the following reasons:
- History of cardiovascular, metabolic, resp...

Participants with or without multiple sclerosis are needed for this research study on audio-visual cognition. Participants will be asked to complete some short questionnaires and cognitive tasks over the span of approximately 2-3 hours. All testing will be completed in one session at the University at Buffalo's Division of Cognitive and Behavioral Neurosciences Laboratories. Read More

-Age range 20-65 years
-Normal Hearing and Vision
-DO NOT have the following: severe psychiatric disorder, alcohol or substance abuse or dependence, history of traumatic head injury, neurological disturbances other than multiple sclerosis.

Study to assess the effect of dapagliflozin as compared with placebo in patients with heart failure who have been stabilized during hospitalization for acute heart failure. Patients will be followed for a maximum of 2 months. Read More

1. Currently hospitalized with AHF with symptoms of AHF.
2. LVEF <40% within the past 12 months
3. Elevated NT-proBNP, >1600 pg/ml
4. > 18 years of age
5. eGFR >30

This clinical study investigates a new treatment for prostate cancer. ODM-208 (CYP11A1 inhibitor) is the oral study medication that will be taken together with oral glucocorticoid (dexamethasone) and mineralocorticoid (fludrocortisone) replacement therapy. The purpose of this study is to find a safe and effective dose of ODM-208 for the treatment of prostate cancer. The purpose of this study is also to use the results of this study to support development programs of CYP11A1 inhibitors in prostate cancer and other relevant indications. Read More

1) Males greater than or equal to 18 years. 2) Metastatic disease documented either by a positive bone scan, CT, PET/CT or MRI scan 3) Treatment with at least 1 line of taxane-based chemotherapy in castration-sensitive prostate cancer (CSPC) or in CRPC

-Adults ages 18-80
-Has a single unruptured target intracranial aneurysm (IA) located on the internal carotid artery (ICA) or its branches.